The Prof G Pod with Scott Galloway - No Mercy / No Malice: America’s Best Bet

Episode Date: October 25, 2025

As read by George Hahn. https://www.profgalloway.com/americas-best-bet/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode is brought to you by Peloton. A new era of fitness is here. Introducing the new Peloton Cross Training Tread Plus, powered by Peloton IQ. Built for breakthroughs, with personalized workout plans, real-time insights, and endless ways to move. Lift with confidence, while Peloton IQ counts reps, corrects form, and tracks your progress. Let yourself run, lift, flow, and go. Explore the new Peloton Cross Training Tread Plus at OnePeloton.ca. Is it the matcha, or am I this energized from scoring three Sephora holiday gift sets?

Definitely the sets. Full size and minis bundled together? What a steal. And that packaging? So cute. It practically wraps itself. And I know I should be giving them away, but I'm keeping the Summer Fridays and Rare Beauty by Selena Gomez. I don't blame you. The best holiday beauty sets are only at Sephora. Gift sets from Summer Fridays, Rare Beauty, Way, and more are going fast. Get full-sized favorites and must-have minis bundled for more value.

Shop before they're gone. In-store online at Sephora.com. Fly Air Transat Seven Time winners Champions Fly the seven time world's best leisure airline champions Air Transat I'm Scott Galloway

and this is no mercy, no malice. America has become a giant bet on AI. A better bet? GLP won. America's best bet as read by George Haan. America is now one giant bet on AI. If not for the magnificent 10, the markets would be flat for the year.

There's a different technology that offers more asymmetric upside. If we want to transform the economy, and the well-being of Americans, we should focus on GLP-1, not GPT-5. More than 40% of American adults, 100 million people, are struggling with obesity. By 2060, half of U.S. adults may be obese. The health care costs of all that extra weight could exceed $20 trillion over that period. Our debt, $5 trillion in receipts versus $7 trillion in spending, has become the IED of our economy. We don't know when or why it will detonate.

If we're going to have an adult conversation regarding spending, all roads lead to the same place. Health care. We spend $13,000 per person versus $6,500 in the rest of the G7. Matching the efficiency of our peers would save us $2 trillion a year. Why do we spend double to die sooner while experiencing more anxiety, depression, and chronic illness? Our problem isn't vaccines, food dyes, or Tylenol. It's fat. The Milken Institute and McKinsey have estimated that obesity costs us about $400 billion annually in direct medical costs, and lost productivity.

U.S. health care isn't about caring for health. It's about monetizing it. Just as big tech found the gangster app for shareholder value, rage, the industrial food, hospital, and pharma complexes have found obesity. They get you addicted to sugar and salt, then hand you to the non-health complex

for replacements, dialysis, and statins. They've even rebranded disease, as identity. You're not obese. You're living your truth. No, you're finding diabetes. McDonald's and Coca-Cola celebrate obesity so United Healthcare can monetize it. These stocks aren't equities. They're obesity indices. We know exercise, healthier food, and less screen time help, but they're not enough. The good news? Obesity may have peace. in the U.S., and we have the tools to actually reverse it. Pushing for a radically lower price and rolling out weight loss drugs to tens of millions

of Americans could be revolutionary, possibly the best civic investment in recent history. In some, our instincts have not kept pace with industrial production, and we gorge. GLP-1s put scaffolding on our instincts. Most of us have friends or colleagues we barely recognize after they've taken novel weight loss drugs. By mimicking a hormone called GLP1, the medicines suppress hunger and make us feel fuller, longer. The results are dramatic, 15% to 20% reductions in body weight. Yet, uptake remains small relative to the tens of millions who could benefit. Coverage is patchy.

Only 30% to 40% of commercial plans and 14 state Medicaid programs cover the cost of GLP-1s for obesity. The administration is considering a pilot to expand coverage under Medicaid and Medicare, a shift in policy after rejecting a Biden-era plan that would have cost $35 billion over 10 years. Prices need to fall for the math to work. If Medicare began covering GLP-1s, researchers estimate three-year-old. million beneficiaries would start using them over the next decade at a gross cost of $66 billion and savings in avoiding health care spending of $18 billion for a net price tag of $48 billion. Costs are moving in the right direction. Wagovi and Ozempic now run under $7,000 a year.

Costco offers a monthly supply of obesity drugs for $499. and competition from Lilly and others is driving prices down. More than 100 next-generation obesity drugs are in development, including pill versions. President Trump, on October 16, vowed to slash GLP1 prices to $150 a month to match the expense in other developed nations, but no deal yet exists with drug makers. Investors, however, took him seriously, shares of Novo Nordisk, and Lilly dropped sharply on the news. Economist Emily Oster argues the budgetary worries of expanding access are overstated.

Medicaid tends to pay far less than private insurers, and a typical 53% discount could drop monthly costs to $235. If 10% of eligible patients took the drugs, it would raise Medicaid spending, by just 0.4%. The concerns also missed the upside. About 5 million U.S. adults use GLP-1s today. If 30 million did, Goldman Sachs estimates GDP would rise as much as 0.8%.

At 60 million, the increase could exceed 1%. America isn't the only country fighting this epidemic. In Britain, obesity costs the economy 31 billion pounds a year in lower productivity, sick days, and early deaths. We've created a food system that's poisoning our population and bankrupting the state, says Henry Dimbleby, co-founder of Leon Restaurants, which bills itself as a purveyor of fast but healthy meals. These drugs aren't a silver bullet, but they are a bullet. many people quit taking them within a year or two, often because of cost or gastrointestinal side effects, and lasting success still requires exercise and diet changes. But alongside those

measures, GLP-1s may be the key to fighting a complex disease rooted in physiology, environment, and policy as much as behavior. In a society addicted to ultra-processed food and sedentary hours lost in front of screens, we need new weapons. Former FDA Commissioner David Kessler calls GLP-1s a way to diffuse the ultra-formulated food bombs that have hijacked our health. RFK Jr. has called for lifestyle changes while cutting NIH funding,

the moral equivalent of telling people to lift weights while closing the gym. The administration's Secretary of War, Pete Hegseth, has shamed fat generals but offers no help other than performative masculinity. Scaling access could prevent adult obesity from topping 50% and push it back toward 30%. Giving 10 million Americans' GLP-1s

and lowering their monthly cost to $50 would run $12 billion over two years. That's a bargain. Targeting the patient, most likely to benefit would improve returns further. Obesity shortens life expectancy by up to 10 years, partly because it increases the risk for more than a dozen types of cancer. Reducing its prevalence would yield massive health and productivity gains over the next 30 years.

I'm sticking with the thesis I shared with Bill Maher two years ago. GLP-1s will have a bigger impact on the real economy than AI. OpenAI Sam Altman calls Sora the most powerful imagination engine ever built In reality, it's an endless feed of digital slop Further blurring the truth The real engine of progress comes in a syringe Maybe we should put it in the water

Researchers are aiming to preserve muscle And overcome one of the drawbacks with the first treatments or eliminate injections altogether. They're also testing GLP-1s to treat conditions beyond obesity. Novo Nordisk is betting its drugs can work against Alzheimer's. Whether or not these efforts succeed, the trajectory is clear. This technology could reverse the most expensive disease in history. America's two great growth engines are rage and carbs.

AI monetizes the former, the food complex, the latter. GLP-1s may finally break the loop, shrinking our waste lines, cutting costs, and reminding us that progress isn't digital. It's biological. The next great platform isn't the neural net. It's the needle. Life is so rich.

Rinse takes your laundry and hand delivers it to your door, expertly cleaned and folded. So you could take the time once spent folding and sorting and waiting to finally pursue a whole new version of you. Like T-time U. Or this T-time U. Or even this T-Time U. Said you hear about Dave?

Or even T-Time-T-Time. tea time you. Mmm. So update on Dave. It's up to you. We'll take the laundry. Rinse. It's time to be great.